Latest news for Zephyr Energy (OTC:ZPHRF) Stock

Zephyr Energy PLC is a technology-led oil and gas company focused on responsible resource development from carbon-neutral operations in the Rocky Mountain region of the United States. The company's main operating segment is the exploration, development, and production of oil and gas resources, based in the USA. It generates the revenue from Crude oil, Natural gas, and Natural gas liquids.

Zephyr Energy PLC

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Horace Mann Educators (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMN#NYSE">HMN</a>) with a Outperform and lowers the price target from $42 to $40.

News

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on Horace Mann Educators, Lowers Price Target to $40

Wells Fargo analyst Timur Braziler maintains Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) with a Equal-Weight and raises the price target from $22 to $26.

COLB

Wells Fargo Maintains Equal-Weight on Columbia Banking System, Raises Price Target to $26

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Heritage Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFWA#NASDAQ">HFWA</a>) with a Market Perform and raises the price target from $20 to $23.

HFWA

Keefe, Bruyette & Woods Maintains Market Perform on Heritage Financial, Raises Price Target to $23

Management

LAES

SEALSQ Appoints Katsu Miyahata As Sales Director And Representative Director For Japan; Miyahata To Lead Expansion Of IoT Security And Brand Enhancement Operations

Oxford Lane Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXLC#NASDAQ">OXLC</a>) reported quarterly earnings of $0.41 per share. This is a 4.65 percent decrease over earnings of $0.43 per share from the same period last year. The company reported $89.80 million in sales this quarter. This is a 27.38 percent increase over sales of $70.50 million the same period last year.

Earnings

OXLC

Oxford Lane Capital Q1 Adj $0.41 Down From $0.43 YoY, Sales $89.80M Up From $70.50M YoY

Wells Fargo analyst Jonathan Reeder maintains SJW Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NYSE">SJW</a>) with a Equal-Weight and raises the price target from $62 to $63.

Wells Fargo Maintains Equal-Weight on SJW Gr, Raises Price Target to $63

Friday,&nbsp;Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;posted second-quarter revenues of $12.20 billion, beating the consensus of $11.55 billion, an increase of 9% year-over-year, or 11% when adjusted for foreign exchange impacts, primarily driven by the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Growth Portfolio and&nbsp;Eliquis</a>.
Growth Portfolio worldwide revenues increased to $5.6 billion compared to $4.7 billion a year ago, representing growth of 18% on a reported basis or 21% when adjusted for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39980444/bristol-myers-squibb-reports-second-quarter-financial-results-for-2024" rel="noreferrer noopener">foreign exchange impacts</a>.
Growth Portfolio revenues were primarily driven by higher demand for&nbsp;Opdivo,&nbsp;Reblozyl, Camzyos, and&nbsp;Opdualag,&nbsp;partially offset by&nbsp;Abecma.
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39454533/fda-approves-bristol-myers-squibbs-combination-therapy-for-colorectal-cancer-patients-with-certai" rel="noreferrer noopener">FDA Approves Bristol Myers Squibb&#8217;s Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation</a>.
Opdivo sales incresaed 11% to $2.39 billion. Abecma sales fell 28% to $95 million.
Revenues for the Legacy Portfolio in the second quarter were $6.6 billion compared to $6.5 billion a year ago, representing growth of 2% on a reported basis, or 3% when adjusted for foreign exchange impacts.
Legacy Portfolio revenues were driven by higher demand for&nbsp;Eliquis&nbsp;and&nbsp;Pomalyst, partially offset by a decline in&nbsp;Revlimid&nbsp;due to generic erosion. Eliquis sales were up 7% to $3.42 billion.
The company reported an adjusted EPS of $2.07, compared to an income of&nbsp;$1.75 a year&nbsp;ago, beating the consensus of $1.63.
&#8220;Our second quarter results reflect progress against our strategy to position BMS for long-term, sustainable growth. As we move into the second half of the year, we remain focused on prioritizing opportunities with the greatest growth potential and impact for patients, including the anticipated U.S. launch of KarXT. We&#8217;re also driving operational excellence throughout the company, becoming more agile and strengthening execution,&#8221; said Christopher Boerner, board chair and CEO.
Guidance:&nbsp;Bristol Myers Squibb revises 2024 adjusted EPS guidance to $0.60-$0.90 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38437857/bristol-myers-squibb-swings-to-quarterly-loss-after-string-of-multi-billion-acquisitions" rel="noreferrer noopener">versus prior guidance</a> of $0.40-$0.70 and consensus Of $0.51.
For 2024, the U.S. drug maker expects revenue growth to be at the upper end of the previously provided low single-digit range.
Price Action: BMY stock is up 5.17% at $47.61 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/05/39118061/fda-expands-approval-for-bristol-myers-squibbs-breyanzi-making-car-t-cell-therapy-available-for-b" target="_blank" rel="noreferrer noopener">FDA Expands Approval For Bristol Myers Squibb&#8217;s Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies</a>.</li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Movers

General

Bristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast

Keefe, Bruyette &amp; Woods analyst Tommy McJoynt reiterates Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Outperform and lowers the price target from $85 to $84.

Reiteration

GSHD

Keefe, Bruyette & Woods Reiterates Outperform on Goosehead Insurance, Lowers Price Target to $84

RBC Capital analyst Greg Pardy reiterates Athabasca Oil (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATH#TSX">ATH</a>) with a Sector Perform and maintains C$6 price target.

TSX:ATH

RBC Capital Reiterates Sector Perform on Athabasca Oil, Maintains C$6 Price Target

Wells Fargo analyst Roger Read maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Equal-Weight and raises the price target from $156 to $165.

Wells Fargo Maintains Equal-Weight on Valero Energy, Raises Price Target to $165

MEDS

TRxADE Health Closes  Business Combination With Scienture In $103M All-Stock Transactoin; TRxADE Acquired All Of Scienture's Assets In Exchange For TRxADE Shares

Wells Fargo analyst Neil Kalton maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Overweight and raises the price target from $21 to $22.

Wells Fargo Maintains Overweight on PG&E, Raises Price Target to $22

RBC Capital analyst Greg Pardy reiterates Baytex Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTE#TSX">BTE</a>) with a Outperform and maintains C$6.5 price target.

TSX:BTE

RBC Capital Reiterates Outperform on Baytex Energy, Maintains C$6.5 Price Target

Guidance

TNET

TriNet Continues To Expect FY24 Total Revenues To Be Down 1% To Up 4%; Adj EPS Of $5.25 - $6.80 (Est $5.94)

First Hawaiian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NASDAQ">FHB</a>) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.43 by 11.63 percent. This is a 2.04 percent decrease over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $204.62 million which beat the analyst consensus estimate of $203.33 million by 0.63 percent. This is a 1.29 percent decrease over sales of $207.29 million the same period last year.

Earnings Beats

First Hawaiian Q2 EPS $0.48 Beats $0.43 Estimate, Sales $204.62M Beat $203.33M Estimate

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Five Star (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBC#NASDAQ">FSBC</a>) with a Market Perform and raises the price target from $27 to $31.

FSBC

Keefe, Bruyette & Woods Maintains Market Perform on Five Star, Raises Price Target to $31

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.
Shares of DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) fell sharply during Friday's pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued <a href="https://www.benzinga.com/news/earnings/24/07/39971462/dexcom-stock-drops-after-mixed-q2-results-weak-forward-guidance">weak FY24 revenue guidance</a>.
DexCom reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 39 cents. Quarterly sales came in at $1.004 billion which missed the analyst consensus estimate of $1.036 billion.
DexCom sees third-quarter revenue in a range of $975 million to $1 billion, versus the $1.15 billion estimate, and full-year revenue in a range of $4. billion to $4.05 billion, versus the $4.33 billion estimate.
DexCom shares dipped 37% to $68.00 in the pre-market trading session.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares declined 21.5% to $8.00 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>Ur-Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URG#NYSE">URG</a>) shares fell 9.2% to $1.18 in pre-market trading after the company announced a proposed public offering of common shares.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares declined 9% to $36.99 in pre-market trading. Tandem Diabetes Care will release its second quarter results after the closing bell on Thursday, Aug. 1.</li>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares dipped 8.9% to $5.01 in pre-market trading after gaining 5% on Thursday.</li>
<li>Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) shares declined 8.1% to $44.15 in pre-market trading following a second-quarter earnings miss.</li>
<li>Carter&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares fell 7.4% to $55.40 in pre-market trading following weak quarterly sales.</li>
<li>Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) shares fell 4.4% to $12.52 in pre-market trading. Indivior shares jumped 20% on Thursday after the company reported better-than-expected second-quarter financial results and announced an accelerated $100 million share repurchase program.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39978094/s-p-500-nasdaq-settle-lower-as-tech-stocks-continue-to-falter-greed-index-in-fear-zone">S&amp;P 500, Nasdaq Settle Lower As Tech Stocks Continue To Falter: Greed Index In &#8216;Fear&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

DXCM

INDV

MGNX

TNDM

ZYXI

DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Trading Halt: Halted at 8:05:00 a.m. ET - Trading Halt: Halt News Pending

Wells Fargo analyst Neil Kalton maintains Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) with a Overweight and raises the price target from $86 to $87.

Wells Fargo Maintains Overweight on Edison Intl, Raises Price Target to $87

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Deutsche Bank analyst Scott Deuschle downgraded the rating for L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) from Buy to Hold, but increased the price target from $245 to $257. L3Harris Technologies shares gained 2.6% to settle at $243.27 on Thursday. See how other analysts view this stock. <a href="https://www.benzinga.com/quote/LHX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst David George downgraded Huntington Bancshares Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) from Outperform to Neutral and maintained a price target of $15. Huntington Bancshares shares gained 0.9% to close at $15.06 on Thursday. <a href="https://www.benzinga.com/quote/HBAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Michael Linenberg downgraded the rating for Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) from Buy to Hold, while lowering the price target from $32 to $29. Southwest Airlines shares rose 5.5% to close at $28.08 on Thursday. See how other analysts view this stock.</li>
<li>Jefferies analyst Anna Glaessgen downgraded Brunswick Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BC#NYSE">BC</a>) from Buy to Hold and lowered the price target from $115 to $70. Brunswick shares rose 7.5% to close at $79.02 on Thursday. <a href="https://www.benzinga.com/quote/BC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan analyst Robbie Marcus downgraded the rating for DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) from Overweight to Neutral, while cutting the price target from $145 to $75. DexCom shares fell 3.7% to close at $107.85 on Thursday. <a href="https://www.benzinga.com/quote/DXCM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39958830/top-3-defensive-stocks-that-are-ticking-portfolio-bombs">Top 3 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Downgrades

HBAN

This Southwest Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Zephyr Energy "going to push forward" in second half

Zephyr Energy to proceed with redrill at State 36-2 well

Zephyr Energy reports strong fourth quarter with production increase and positive outlook

Commodities

Press Releases

EnerCom Announces Chris Wright, Chairman and Chief Executive Officer of Liberty Energy, as Keynote Speaker at the 29th Annual EnerCom Denver - The Energy Investment Conference

Small Cap

EnerCom Announces Unparalleled Networking Opportunities at the 29th Annual EnerCom Denver - The Energy Investment Conference, Including Charity Golf Tournament, Monday Cocktail Mixer, Casino Night, and Last Day Reception

The 29th Annual EnerCom Denver - The Energy Investment Conference to Host The Energy Transition and Emerging Technology Session Featuring Start-Up Energy and Technology Companies

Presentation Times and Schedule for Participating Companies Now Posted on the Conference Website for 29th Annual EnerCom Denver - The Energy Investment Conference

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Zephyr Energy

News

Latest news for Zephyr Energy (OTC:ZPHRF) Stock